FDA targets compounded GLP-1 drugs
The US Food and Drug Administration proposed on April 30, 2026, to remove semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. The change would prevent outsourcing facilities from compounding these drugs from bulk substances. Semaglutide is the active ingredient in Ozempic and Wegovy. Tirzepatide is the active ingredient in Mounjaro and Zepbound.
The FDA said there is no clinical need for outsourcing facilities to compound these medications from bulk substances. The move affects a growing market of compounded GLP-1 drugs that patients buy at lower prices than the brand-name versions. Compounded tirzepatide has been available for $150 to $300 per month, compared to more than $1,000 for the branded product.
GLP-1 drugs see massive demand
GLP-1 receptor agonists were approved 20 years ago for diabetes treatment. Today, more than 30 million Americans use these drugs for weight loss. Studies have found that GLP-1 drugs may also lower breast cancer risk and help treat other obesity-related diseases, including some cancers.
The high cost of brand-name GLP-1 drugs has driven many patients to seek cheaper compounded versions. Drugmakers have struggled to keep up with demand, leading to periodic shortages that allowed compounding pharmacies to legally produce alternatives.
Industry and patient impact
The FDA proposal would restrict compounding to patient-specific prescriptions rather than bulk production. Compounding pharmacies and telehealth companies that sell compounded GLP-1 drugs face a major disruption to their business models. Patient advocates say the move could limit access for people who cannot afford brand-name versions.
The FDA is accepting public comments on the proposal. A final decision is expected later this year. The branded drug manufacturers, including Novo Nordisk and Eli Lilly, have supported tighter restrictions on compounding.